Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein En
Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio PartnersCompany’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) moleculesFounding team comprised of world-class scientific leadersWATERTOWN, Mass.--(BUSINESS WIRE)--Entact B...
Source: pharmiweb.com